Lamotrigine-induced Stevens-Johnson syndrome

A case of lamotrigine-induced Stevens-Johnson syndrome (SJS) is reported. A 29-year-old woman with a medical history of schizoaffective disorder arrived at the emergency department with a severe generalized skin reaction. Three to four days prior she had noticed bumps on her lips that had spread to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of health-system pharmacy 2007-02, Vol.64 (3), p.273-275
Hauptverfasser: Hilas, Olga, Charneski, Lisa
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 275
container_issue 3
container_start_page 273
container_title American journal of health-system pharmacy
container_volume 64
creator Hilas, Olga
Charneski, Lisa
description A case of lamotrigine-induced Stevens-Johnson syndrome (SJS) is reported. A 29-year-old woman with a medical history of schizoaffective disorder arrived at the emergency department with a severe generalized skin reaction. Three to four days prior she had noticed bumps on her lips that had spread to her oral mucosa. She had also developed a diffuse, erythematous, pruritic full-body rash involving the palms of her hands and the soles of her feet and began to feel feverish. Her medications at admission included aripiprazole 30 mg p.o. daily, escitalopram 10 mg p.o. daily, and lamotrigine 75 mg p.o. daily. Lamotrigine was the only new medication, initiated four weeks before this admission. The dermatology service confirmed the diagnosis of SJS using punch biopsy. Lamotrigine was suspected to be the culprit and was discontinued immediately. The patient was given oral prednisone 40 mg and intravenous fluids. Hydroxyzine was given for pruritus, and petroleum jelly and viscous lidocaine were applied to her lips. On hospital day 2, her symptoms and dermatological manifestations improved, but she continued to complain about irritation and slight pain of the mouth. She then received a mouthwash consisting of diphenhydramine, viscous lidocaine, and sodium bicarbonate. On hospital day 3, the patient had improved substantially and was discharged home. Reports of these dermatological reactions in patients receiving lamotrigine for the treatment of bipolar disorder are limited. Dosing, prompt recognition, and patient education are crucial for preventing morbidity and mortality associated with the development of serious cutaneous reactions. SJS was associated with lamotrigine use, despite appropriate dosing and dosage adjustment.
doi_str_mv 10.2146/ajhp060071
format Article
fullrecord <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A165431754</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A165431754</galeid><sourcerecordid>A165431754</sourcerecordid><originalsourceid>FETCH-LOGICAL-c382t-acd3092ddba971bceda8b7765d11c0c9a06fdc892a290570dd64413bcfbbbf333</originalsourceid><addsrcrecordid>eNptkFtLw0AQhRdRbK2--AOkIL6IqbO7yW7yWIpXCj6oz8ve0mxJNiXbGvrvXUlBBBmYGYZvDoeD0CWGGcEpu5fragMMgOMjNMYZzRJSABzHHXiREMjJCJ2FsAbAJAd2ikaYkzTNORuju6Vs2m3nVs7bxHmz09ZM37f2y_qQvLaVD62fhr03XdvYc3RSyjrYi8OcoM_Hh4_Fc7J8e3pZzJeJpjnZJlIbCgUxRsmCYxUVZa44Z5nBWIMuJLDS6LwgMvrMOBjD0hRTpUulVEkpnaDrQXclayucL6NDqRsXtJhjlqUU89gmaPYPFcvYxunW29LF-5-H2-FBd20InS3FpnON7PYCg_hJUvwmGeGrAd7sVGPNL3qILgI3A1C5VdW7zorQyLqOOBF937NUUEE4pd8FaXqY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Lamotrigine-induced Stevens-Johnson syndrome</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Hilas, Olga ; Charneski, Lisa</creator><creatorcontrib>Hilas, Olga ; Charneski, Lisa</creatorcontrib><description>A case of lamotrigine-induced Stevens-Johnson syndrome (SJS) is reported. A 29-year-old woman with a medical history of schizoaffective disorder arrived at the emergency department with a severe generalized skin reaction. Three to four days prior she had noticed bumps on her lips that had spread to her oral mucosa. She had also developed a diffuse, erythematous, pruritic full-body rash involving the palms of her hands and the soles of her feet and began to feel feverish. Her medications at admission included aripiprazole 30 mg p.o. daily, escitalopram 10 mg p.o. daily, and lamotrigine 75 mg p.o. daily. Lamotrigine was the only new medication, initiated four weeks before this admission. The dermatology service confirmed the diagnosis of SJS using punch biopsy. Lamotrigine was suspected to be the culprit and was discontinued immediately. The patient was given oral prednisone 40 mg and intravenous fluids. Hydroxyzine was given for pruritus, and petroleum jelly and viscous lidocaine were applied to her lips. On hospital day 2, her symptoms and dermatological manifestations improved, but she continued to complain about irritation and slight pain of the mouth. She then received a mouthwash consisting of diphenhydramine, viscous lidocaine, and sodium bicarbonate. On hospital day 3, the patient had improved substantially and was discharged home. Reports of these dermatological reactions in patients receiving lamotrigine for the treatment of bipolar disorder are limited. Dosing, prompt recognition, and patient education are crucial for preventing morbidity and mortality associated with the development of serious cutaneous reactions. SJS was associated with lamotrigine use, despite appropriate dosing and dosage adjustment.</description><identifier>ISSN: 1079-2082</identifier><identifier>EISSN: 1535-2900</identifier><identifier>DOI: 10.2146/ajhp060071</identifier><identifier>PMID: 17244876</identifier><language>eng</language><publisher>England: American Society of Health-System Pharmacists</publisher><subject>Adult ; Anticonvulsants - administration &amp; dosage ; Anticonvulsants - adverse effects ; Case studies ; Complications and side effects ; Dosage and administration ; Female ; Humans ; Lamotrigine ; New York City ; Risk factors ; Stevens-Johnson syndrome ; Stevens-Johnson Syndrome - chemically induced ; Triazines - administration &amp; dosage ; Triazines - adverse effects</subject><ispartof>American journal of health-system pharmacy, 2007-02, Vol.64 (3), p.273-275</ispartof><rights>COPYRIGHT 2007 Oxford University Press</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c382t-acd3092ddba971bceda8b7765d11c0c9a06fdc892a290570dd64413bcfbbbf333</citedby><cites>FETCH-LOGICAL-c382t-acd3092ddba971bceda8b7765d11c0c9a06fdc892a290570dd64413bcfbbbf333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17244876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hilas, Olga</creatorcontrib><creatorcontrib>Charneski, Lisa</creatorcontrib><title>Lamotrigine-induced Stevens-Johnson syndrome</title><title>American journal of health-system pharmacy</title><addtitle>Am J Health Syst Pharm</addtitle><description>A case of lamotrigine-induced Stevens-Johnson syndrome (SJS) is reported. A 29-year-old woman with a medical history of schizoaffective disorder arrived at the emergency department with a severe generalized skin reaction. Three to four days prior she had noticed bumps on her lips that had spread to her oral mucosa. She had also developed a diffuse, erythematous, pruritic full-body rash involving the palms of her hands and the soles of her feet and began to feel feverish. Her medications at admission included aripiprazole 30 mg p.o. daily, escitalopram 10 mg p.o. daily, and lamotrigine 75 mg p.o. daily. Lamotrigine was the only new medication, initiated four weeks before this admission. The dermatology service confirmed the diagnosis of SJS using punch biopsy. Lamotrigine was suspected to be the culprit and was discontinued immediately. The patient was given oral prednisone 40 mg and intravenous fluids. Hydroxyzine was given for pruritus, and petroleum jelly and viscous lidocaine were applied to her lips. On hospital day 2, her symptoms and dermatological manifestations improved, but she continued to complain about irritation and slight pain of the mouth. She then received a mouthwash consisting of diphenhydramine, viscous lidocaine, and sodium bicarbonate. On hospital day 3, the patient had improved substantially and was discharged home. Reports of these dermatological reactions in patients receiving lamotrigine for the treatment of bipolar disorder are limited. Dosing, prompt recognition, and patient education are crucial for preventing morbidity and mortality associated with the development of serious cutaneous reactions. SJS was associated with lamotrigine use, despite appropriate dosing and dosage adjustment.</description><subject>Adult</subject><subject>Anticonvulsants - administration &amp; dosage</subject><subject>Anticonvulsants - adverse effects</subject><subject>Case studies</subject><subject>Complications and side effects</subject><subject>Dosage and administration</subject><subject>Female</subject><subject>Humans</subject><subject>Lamotrigine</subject><subject>New York City</subject><subject>Risk factors</subject><subject>Stevens-Johnson syndrome</subject><subject>Stevens-Johnson Syndrome - chemically induced</subject><subject>Triazines - administration &amp; dosage</subject><subject>Triazines - adverse effects</subject><issn>1079-2082</issn><issn>1535-2900</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkFtLw0AQhRdRbK2--AOkIL6IqbO7yW7yWIpXCj6oz8ve0mxJNiXbGvrvXUlBBBmYGYZvDoeD0CWGGcEpu5fragMMgOMjNMYZzRJSABzHHXiREMjJCJ2FsAbAJAd2ikaYkzTNORuju6Vs2m3nVs7bxHmz09ZM37f2y_qQvLaVD62fhr03XdvYc3RSyjrYi8OcoM_Hh4_Fc7J8e3pZzJeJpjnZJlIbCgUxRsmCYxUVZa44Z5nBWIMuJLDS6LwgMvrMOBjD0hRTpUulVEkpnaDrQXclayucL6NDqRsXtJhjlqUU89gmaPYPFcvYxunW29LF-5-H2-FBd20InS3FpnON7PYCg_hJUvwmGeGrAd7sVGPNL3qILgI3A1C5VdW7zorQyLqOOBF937NUUEE4pd8FaXqY</recordid><startdate>20070201</startdate><enddate>20070201</enddate><creator>Hilas, Olga</creator><creator>Charneski, Lisa</creator><general>American Society of Health-System Pharmacists</general><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20070201</creationdate><title>Lamotrigine-induced Stevens-Johnson syndrome</title><author>Hilas, Olga ; Charneski, Lisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c382t-acd3092ddba971bceda8b7765d11c0c9a06fdc892a290570dd64413bcfbbbf333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Anticonvulsants - administration &amp; dosage</topic><topic>Anticonvulsants - adverse effects</topic><topic>Case studies</topic><topic>Complications and side effects</topic><topic>Dosage and administration</topic><topic>Female</topic><topic>Humans</topic><topic>Lamotrigine</topic><topic>New York City</topic><topic>Risk factors</topic><topic>Stevens-Johnson syndrome</topic><topic>Stevens-Johnson Syndrome - chemically induced</topic><topic>Triazines - administration &amp; dosage</topic><topic>Triazines - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hilas, Olga</creatorcontrib><creatorcontrib>Charneski, Lisa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American journal of health-system pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hilas, Olga</au><au>Charneski, Lisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lamotrigine-induced Stevens-Johnson syndrome</atitle><jtitle>American journal of health-system pharmacy</jtitle><addtitle>Am J Health Syst Pharm</addtitle><date>2007-02-01</date><risdate>2007</risdate><volume>64</volume><issue>3</issue><spage>273</spage><epage>275</epage><pages>273-275</pages><issn>1079-2082</issn><eissn>1535-2900</eissn><abstract>A case of lamotrigine-induced Stevens-Johnson syndrome (SJS) is reported. A 29-year-old woman with a medical history of schizoaffective disorder arrived at the emergency department with a severe generalized skin reaction. Three to four days prior she had noticed bumps on her lips that had spread to her oral mucosa. She had also developed a diffuse, erythematous, pruritic full-body rash involving the palms of her hands and the soles of her feet and began to feel feverish. Her medications at admission included aripiprazole 30 mg p.o. daily, escitalopram 10 mg p.o. daily, and lamotrigine 75 mg p.o. daily. Lamotrigine was the only new medication, initiated four weeks before this admission. The dermatology service confirmed the diagnosis of SJS using punch biopsy. Lamotrigine was suspected to be the culprit and was discontinued immediately. The patient was given oral prednisone 40 mg and intravenous fluids. Hydroxyzine was given for pruritus, and petroleum jelly and viscous lidocaine were applied to her lips. On hospital day 2, her symptoms and dermatological manifestations improved, but she continued to complain about irritation and slight pain of the mouth. She then received a mouthwash consisting of diphenhydramine, viscous lidocaine, and sodium bicarbonate. On hospital day 3, the patient had improved substantially and was discharged home. Reports of these dermatological reactions in patients receiving lamotrigine for the treatment of bipolar disorder are limited. Dosing, prompt recognition, and patient education are crucial for preventing morbidity and mortality associated with the development of serious cutaneous reactions. SJS was associated with lamotrigine use, despite appropriate dosing and dosage adjustment.</abstract><cop>England</cop><pub>American Society of Health-System Pharmacists</pub><pmid>17244876</pmid><doi>10.2146/ajhp060071</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1079-2082
ispartof American journal of health-system pharmacy, 2007-02, Vol.64 (3), p.273-275
issn 1079-2082
1535-2900
language eng
recordid cdi_gale_infotracmisc_A165431754
source MEDLINE; Oxford University Press Journals All Titles (1996-Current)
subjects Adult
Anticonvulsants - administration & dosage
Anticonvulsants - adverse effects
Case studies
Complications and side effects
Dosage and administration
Female
Humans
Lamotrigine
New York City
Risk factors
Stevens-Johnson syndrome
Stevens-Johnson Syndrome - chemically induced
Triazines - administration & dosage
Triazines - adverse effects
title Lamotrigine-induced Stevens-Johnson syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T03%3A47%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lamotrigine-induced%20Stevens-Johnson%20syndrome&rft.jtitle=American%20journal%20of%20health-system%20pharmacy&rft.au=Hilas,%20Olga&rft.date=2007-02-01&rft.volume=64&rft.issue=3&rft.spage=273&rft.epage=275&rft.pages=273-275&rft.issn=1079-2082&rft.eissn=1535-2900&rft_id=info:doi/10.2146/ajhp060071&rft_dat=%3Cgale_cross%3EA165431754%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17244876&rft_galeid=A165431754&rfr_iscdi=true